Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01516957 · ClinicalTrials.gov registry record · Phase 2

AMG 827 in Subjects With Psoriatic Arthritis

A Phase 2 study, sponsored by Bausch Health Americas.

Terminated
Registry status
Phase 2
Development phase
168
Enrollment target

NCT01516957: Clinical Trial Phase 2 study, sponsored by Bausch Health Americas.

NCT01516957 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 168 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01516957, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.

TERMINATED
Registry status
Phase 2
Development phase
168 participants
Enrollment target

Study Summary

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Primary Outcome

To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20% response at week 12. ACR20 responders are subjects with 20% improvement from baseline based off of percent changes in tender/painful joint count, swollen joint counts, physician global assessment of disease activity, and health assessment questionnaire-disability index.

Interventions

  • DRUG Placebo
  • DRUG AMG 827 140
  • DRUG AMG 827 280
  • DRUG AMG 827 210

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2011-10
Est. Completion 2015-09
Phase Phase 2
Bausch Health Americas

168 total trials

Why NCT01516957 stopped before completion

NCT01516957 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT01516957 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01516957 about?

NCT01516957 is a clinical study titled "AMG 827 in Subjects With Psoriatic Arthritis". The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

What is the current status of trial NCT01516957?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2011-10. Estimated completion is 2015-09.

What interventions are being tested in trial NCT01516957?

The interventions under investigation include: Placebo (DRUG), AMG 827 140 (DRUG), AMG 827 280 (DRUG), AMG 827 210 (DRUG).

Who is sponsoring clinical trial NCT01516957?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01516957's enrollment target sits among peer trials

168 403rd of 2000 higher than 1,595 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

  • NCT03536897 · 168 participants

    IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

  • NCT04078230 · 168 participants · NA

    Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

  • NCT04159168 · 168 participants · NA

    Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01516957, the US trial registry maintained by the National Library of Medicine. NCT01516957 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.